BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange.

biomoti_acquisition_physiomics_cancerOxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of their drugs in a ‘Virtual Tumour’ during preclinical and clinical stages.

Now, Physiomics is aiming to expand its strategy from service provider to having its own oncology pipeline. So, it has proposed to acquire a Biotech already developing cancer therapies – BioMoti, currently based in the Queen Mary Bioenterprises Innovation Centre (London).

ADVERTISEMENT

biomoti_oncojan_cancer_drug_nanoparticles

How Oncojans target tumour cells. (Source: BioMoti)

BioMoti owns Oncojan, a platform to create nanoparticles packages for cancer drugs, coated with tumour-specific antigens. Targeting the therapy to the tumour area both increases and narrows its effect – sparing healthy tissue from toxicity (same strategy that Nanobiotix has, which combines nanotechnology with radiotherapy.

A range of cancer drugs could be adapted to this strategy, from small-molecule therapeutics to larger biologicals – including those already tested and approved.

Physiomics was attracted by the lower risk of Oncojan platform (compared to normal drug discovery), as development is no longer about proving a drug works, but demonstrating the pharmaco-economic and patient benefits of the modified therapy.

If the acquisition goes forward, BioMoti’s drug development would be supported by the ‘Virtual Tumour‘ technology. In the immediate future, this could apply to MOTI1001, its lead candidate targeting ovarian cancer with well-know Taxol drug.

physiomics_pyc_london_stock_biomoti

Stock price of Physiomics in the last few day (top) and since listing (bottom). (Source: Google Finance)

The acquisition proposal will be on the table for the next 6 months, and Physiomics will need to raise £4M (€5M) . This may be a challenge, as this company has seen its value continuously decrease since it was listed on the London Stack Exchange – from a market cap of around €90M in 2005 to just over €1M now, and with stock price oscillating between 0.02 and 0.03 pence (so 0.00002 to 0.00003 pounds – very surprising to have such a low stock price).

This could be an interesting combination of oncology technology platforms. Physiomics intends to conclude the acquisition in August 2016.


Want to know more about BioMoti? Watch our interview of CEO Davidson Ateh – or attend Labiotech Refresh, where he will be one of the speakers


Featured image credit: Mix of Graphics. Cancer Cell © Krishnacreations (Dreamstime ID45675334). Colloidal particle from Zherebetskyy et al. (2014) Hydroxylation of the surface of PbS nanocrystals passivated with oleic acid. Science (doi: 10.1126/science.1252727)
Previous post

From Paris to Berlin: We give you Bettina!

Next post

BioArt: Joana Ricou shows the Beautiful Similarities of the Microbiome

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.